Check Your Eligibility If you're interested in whether an oral GLP-1 medication like orforglipron could be a fit for your weight loss goals, a licensed provider on Mochi Health's telehealth platform can help you understand your options and determine the right path forward
The advantages are substantial
Novo Nordisk's semaglutide beats its counterpart liraglutide to become the next generation of weight loss innovation, and then Eli Lilly's GLP-1R/GIPR dual-target agonist tirzepatide achieves a 22.5% weight loss, surpassing semaglutide's weight loss history
During the study period GLP-1 RA were approved for use only in patients with type 2 diabetes
The required information typically includes: Diagnosis: Documentation of the patients condition, such as type 2 diabetes, obesity, hypertension, or cardiovascular issues, that warrants the use of a GLP-1 medication